Eurizon Capital SGR S.p.A. Sells 101,122 Shares of AbbVie Inc. $ABBV

Eurizon Capital SGR S.p.A. reduced its position in shares of AbbVie Inc. (NYSE:ABBV) by 6.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,414,037 shares of the company’s stock after selling 101,122 shares during the period. AbbVie accounts for about 1.0% of Eurizon Capital SGR S.p.A.’s investment portfolio, making the stock its 19th largest position. Eurizon Capital SGR S.p.A. owned about 0.08% of AbbVie worth $370,620,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of ABBV. Burk Holdings LLC acquired a new position in AbbVie in the 2nd quarter valued at $30,000. Marquette Asset Management LLC boosted its holdings in shares of AbbVie by 52.2% during the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock worth $35,000 after purchasing an additional 48 shares during the last quarter. IMG Wealth Management Inc. grew its position in shares of AbbVie by 3,060.0% in the second quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock valued at $40,000 after purchasing an additional 153 shares during the period. Principia Wealth Advisory LLC grew its position in shares of AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Finally, Tacita Capital Inc purchased a new stake in shares of AbbVie in the second quarter valued at $42,000. 70.23% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at AbbVie

In other news, EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $293.60, for a total value of $11,925,738.40. Following the transaction, the executive vice president directly owned 83,171 shares of the company’s stock, valued at $24,419,005.60. The trade was a 32.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.06% of the stock is owned by corporate insiders.

Key AbbVie News

Investors following ABBV have been watching these news items:

• Positive Sentiment: AbbVie recently raised its 2026 revenue guidance to about $67.8 billion and increased its dividend after reporting third-quarter revenue of $17.4 billion. These updates reinforce the company’s earnings and shareholder-return outlook. Can AbbVie Justify Its Valuation After Raised Guidance and Strong Results?
• Neutral Sentiment: A Crohn’s disease study update drew coverage describing its likely near-term stock impact as limited; it does not appear to materially change the immediate investment outlook. AbbVie Crohn’s Disease Study Update
• Negative Sentiment: Executive Vice President Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. Insider sales can weigh on sentiment, though the filing does not explain the reason for the transaction. SEC Form 4 filing

AbbVie Stock Down 0.1%

ABBV stock opened at $294.75 on Friday. The company has a market cap of $521.01 billion, a price-to-earnings ratio of 50.73, a PEG ratio of 1.34 and a beta of 0.20. The business has a fifty day simple moving average of $274.82 and a 200-day simple moving average of $240.55. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $302.93.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The firm had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. During the same quarter last year, the firm earned $1.86 earnings per share. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, analysts expect that AbbVie Inc. will post 13.98 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be issued a $1.82 dividend. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date is Friday, January 15th. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.5%. AbbVie’s dividend payout ratio (DPR) is 119.10%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ABBV shares. Bank of America reissued a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Cantor Fitzgerald upped their price objective on shares of AbbVie from $290.00 to $325.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. Leerink Partners increased their price objective on shares of AbbVie from $309.00 to $342.00 and gave the stock an “outperform” rating in a report on Monday, November 2nd. Guggenheim raised their target price on shares of AbbVie from $288.00 to $322.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. Finally, Wells Fargo & Company boosted their target price on shares of AbbVie from $300.00 to $340.00 and gave the company an “overweight” rating in a report on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $297.46.

AbbVie Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.